TRIM24 and cancer: Large tertiary-center and longitudinal investigations that examined cancer risk by specific myositis-related antibodies have repeatedly identified anti-TIF1-γ, and in some reports anti-NXP2 or anti-SAE, as the principal cancer-associated MSAs.